Flow cytometric and cytomorphological definition of remission achievement in children with B-lineage acute lymphoblastic leukemia
-
Published:2023-12-20
Issue:4
Volume:22
Page:79-89
-
ISSN:2414-9314
-
Container-title:Pediatric Hematology/Oncology and Immunopathology
-
language:
-
Short-container-title:Voprosy gematologii/onkologii i immunopatologii v pediatrii
Author:
Popov A. M.1ORCID, Tsaur G. A.2, Rumiantseva Yu. V.3ORCID, Bydanov O. I.1ORCID, Verzhbitskaya T. Yu.4ORCID, Movchan L. V.5, Mikhailova E. V.1ORCID, Illarionova O. I.1, Belevtsev M. V.5, Lagoyko S. N.1ORCID, Zharikova L. I.3ORCID, Permikin Zh. V.6, Myakova N. V.1ORCID, Litvinov D. V.3ORCID, Khlebnikova O. P.7, Streneva O. V.4, Arakaev O. R.7, Stolyarova E. A.5, Khachatryan L. A.1ORCID, Ponomareva N. I.8, Aleinikova O. V.1ORCID, Fechina L. G.4ORCID, Novichkova G. A.1ORCID, Karachunskiy A. I.3ORCID
Affiliation:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation 2. Regional Children's Clinical Hospital;
Institute of Medical Cell Technologies;
Ural State Medical University of Ministry of Healthcare of the Russian Federation 3. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;
N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation 4. Regional Children's Clinical Hospital;
Institute of Medical Cell Technologies 5. Belarusian Research Center for Pediatric Oncology, Hematology and Immunology 6. Regional Children's Clinical Hospital;
Ural State Medical University of Ministry of Healthcare of the Russian Federation 7. Regional Children's Clinical Hospital 8. Russian Children's Clinical Hospital of the N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation
Abstract
The achievement of remission at the end of induction (EOI) chemotherapy in patients with acute lymphoblastic leukemia (ALL) is the key parameter of treatment effectiveness evaluation. The aim of the study – defining complete remission by multicolor flow cytometry (MFC) and bone marrow (BM) cytomorphology (CM) at the EOI chemotherapy in children with B-lineage ALL. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included patients of “ALL-MB 2008” and “ALL-MB 2015” trials for whom minimal residual disease (MRD) was evaluated by MFC at the EOI simultaneously with CM BM investigation. Less than 5% blasts in BM and MRD < 1% were established as the remission achievement criteria for CM and MFC respectively. The study group included 1498 children aged from 1 to 18 years (median age was 4 years and 11 months) with B-cell precursor ALL. The overall concordance of MFC and CM was found to be 96.1% (1440 of 1498 patients). In 36 (2.4%) children with MRD ≥ 1%, M1 BM status was observed. In contrast, in 22 (1.5%) patients with M2/M3 BM status by CM, MRD value was below 1%. Treatment outcome was analyzed in 522 patients of “ALL-MB 2008” trial. Children with M2/M3 BM, as well as with MRD ≥ 1% demonstrated dramatically inferior outcome, in comparison to those who achieved remission. The presence of at least one of the mentioned criteria (M2/M3 status by CM or MRD ≥ 1% by MFC) defined a group of 23 (4.4%) patients with very low event-free survival (34.9%, standard error 11.0%) and very high cumulative incidence of relapse (56.4%, standard error 12.0%). For the evaluation of remission achievement, MFC and CM should be applied simultaneously at the EOI. High leukemic burden found by any of these methods is the clear definition of induction failure. MRD detection at the EOI should be implemented in any modern treatment protocol as an obligatory stage of treatment response monitoring and final risk group stratification. Considering the crucial importance of the MRD detection results, this study must be performed only in the reference laboratories of the study groups.
Publisher
Fund Doctors, Innovations, Science for Children
Subject
Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health
Reference45 articles.
1. Schrappe M., Hunger S.P., Pui C.H., Saha V., Gaynon P.S., Baruchel A., et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012; 366 (15): 1371–81. 2. Oudot C., Auclerc M.F., Levy V., Porcher R., Piguet C., Perel Y., et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26 (9): 1496–503. 3. Silverman L.B., Gelber R.D., Young M.L., Dalton V.K., Barr R.D., Sallan S.E. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999; 85 (6): 1395–404. 4. Suzuki N., Yumura-Yagi K., Yoshida M., Hara J., Nishimura S., Kudoh T., et al. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer 2010; 54 (1): 71–8. 5. Buchmann S., Schrappe M., Baruchel A., Biondi A., Borowitz M.J., Campbell M., et al. Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium. Blood 2022; 139 (12): 1785–93.
|
|